drugset / Trial / NCT01297309

A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

NCT01297309

Phase 3 Completed 51 enrolled Shire
NaSingle-groupOpen-labelTreatment

Summary

This study is a long-term, open-label study using NPSP558 for the treatment of adult patients with Hypoparathyroidism.

Timeline

Start
2011-04-06
Primary completion
2018-06-08
Completion
2018-06-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Parathyroid Hormone Protein / enzyme biologic 25 ug Subcutaneous
Subject Parathyroid Hormone Protein / enzyme biologic 50 ug Subcutaneous
Subject Parathyroid Hormone Protein / enzyme biologic 75 ug Subcutaneous
Subject Parathyroid Hormone Protein / enzyme biologic 100 ug Subcutaneous

Indications